Johnson & Johnson stopped its COVID-19 vaccine trial, which began phase 3 testing last month
Symptoms of COVID-19 Poor Marker for SARS-CoV-2 Infection
Only 13.9 percent of individuals with positive test reported specific symptoms on the day of the test
Bedside Tracheotomy Feasible for Critically Ill COVID-19 Patients
No infection identified among surgeons following procedure; postoperative complications rarely seen
CDC: U.S. COVID-19 Deaths Could Reach 233,000 by End of October
And, dual coronavirus-flu vaccine to start human trials
Remdesivir Cuts Time to COVID-19 Recovery
However, no significant difference in mortality found between remdesivir and placebo groups